PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP
NN Shaha, PL Zinzanib,c, TA Eyred, K Izutsue, AJ Alencarf, K Patelg, T Munirh, DE Tsaii, ML Wangj, LYGN Presenterk
a Medical College of Wisconsin, Milwaukee, United States
b IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia Seràgnoli, Italy
c Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy
d Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom
e Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
f Sylvester Comprehensive Cancer Center, Miami, United States
g Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, United States
h Department of Haematology, St. James's University Hospital, Leeds, United Kingdom
i Loxo@Lilly, Indianapolis, United States
j MD Anderson Cancer Center, Houston, United States
k Eli Lilly and Company, Brazil
Ver másRead
1218
Timeswas read the article
441
Total PDF
777
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 7 | 12 | 9 | 21 |
| 2025 6 | 45 | 19 | 64 |
| 2025 5 | 68 | 13 | 81 |
| 2025 4 | 41 | 15 | 56 |
| 2025 3 | 55 | 15 | 70 |
| 2025 2 | 43 | 16 | 59 |
| 2025 1 | 37 | 34 | 71 |
| 2024 12 | 29 | 21 | 50 |
| 2024 11 | 50 | 20 | 70 |
| 2024 10 | 51 | 28 | 79 |
| 2024 9 | 47 | 24 | 71 |
| 2024 8 | 49 | 15 | 64 |
| 2024 7 | 38 | 20 | 58 |
| 2024 6 | 36 | 28 | 64 |
| 2024 5 | 47 | 34 | 81 |
| 2024 4 | 47 | 14 | 61 |
| 2024 3 | 25 | 26 | 51 |
| 2024 2 | 15 | 27 | 42 |
| 2024 1 | 15 | 15 | 30 |
| 2023 12 | 10 | 23 | 33 |
| 2023 11 | 12 | 16 | 28 |
| 2023 10 | 5 | 9 | 14 |
Show all
